Synapse - Jose Baselga

Results (484)

Paclitaxel for breast cancer: The Memorial Sloan-Kettering Cancer Center experience

Conference Paper

Seidman, A. D.; Hudis, C. A.; Raptis, G.; Baselga, J.; Fennelly, D.; Norton, L.
C M P Medica LLC * The Oncology Group (1997)

Fulltext@MSK | Save

HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications

Conference Paper

Baselga, J.; Seidman, A. D.; Rosen, P. P.; Norton, L.
C M P Medica LLC * The Oncology Group (1997)

Fulltext@MSK | Save

Phase II study of semisynthetic paclitaxel in metastatic breast cancer

Journal Article

Hudis, C.; Riccio, L.; Holmes, F.; Seidman, A.; Baselga, J.; Currie, V.; Fennelly, D.; Gilewski, T.; Moynahan, M.; Raptis, G.; more...
European Journal of Cancer (1997)

Fulltext@MSK | Save

PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number- dependent manner

Journal Article

Bos, M.; Mendelsohn, J.; Kim, Y. M.; Albanell, J.; Fry, D. W.; Baselga, J.
Clinical Cancer Research (1997)

Fulltext@MSK | Save

Farnesyl:protein transferase inhibitors (FTIs) block tyrosine kinase signal transduction and act in concert with an anti-EGF receptor antibody to inhibit cancer cell growth

Meeting Abstract

Sepp-Lorenzino, L.; Bos, M.; Ma, Z.; Baselga, J.; Rands, E.; Kohl, N. E.; Oliff, A.; Mendelsohn, J.; Rosen, N.
Proceedings of the American Association for Cancer Research Annual Meeting (1996)

Fulltext@MSK | Save

A tyrosine kinase inhibitor prevents ligand-induced receptor activation and inhibits growth of cancer cell lines expressing the epidermal growth factor receptor

Meeting Abstract

Bos, M. M. E. M.; Mendelsohn, J.; Kim, Y. M.; Fry, D. W.; Baselga, J.
Proceedings of the American Association for Cancer Research Annual Meeting (1996)

Fulltext@MSK | Save

Blockade of epidermal growth factor receptor kinase activity and induction of p27(KIP1)

Meeting Abstract

Wu, X.; Rosen, N.; Fan, Z.; Baselga, J.; Fry, D. W.; Koff, A.; Mendelsohn, J. A.
Proceedings of the American Association for Cancer Research Annual Meeting (1996)

Fulltext@MSK | Save

Event-free survival after sequential dose-dense doxorubicin (A), paclitaxel (T) and cyclophosphamide (C) in women (pts) with ≥ 4 positive (+) axillary lymph nodes (LN)